Khiron Oonchaiyaphum

Khiron begins dispensation of insurance-covered prescriptions in Colombia

Retrieved on: 
Thursday, January 19, 2023
Government, Insurance, Mental health, Quality of life, Chronic pain, Patient, Sleep, Health insurance, Pharmaceutical industry, Khiron Oonchaiyaphum

Following the Government of Colombia's decision on insurance coverage for medical cannabis, Khiron has begun dispensing medical cannabis to its patient base under the new mandate.

Key Points: 
  • Following the Government of Colombia's decision on insurance coverage for medical cannabis, Khiron has begun dispensing medical cannabis to its patient base under the new mandate.
  • ZereniaTM is a healthcare network of specialized clinics focused on treating chronic pain, neurological conditions, mental health, and sleep disorders.
  • It is the leading medical cannabis clinic network in Colombia, as evidenced by its recent contract with Colombia´s largest public insurance company.
  • Alvaro Torres, CEO of Khiron, comments: "Thanks to the wise decision from the Government of Colombia to cover medical cannabis prescriptions, more and more of our patients are leaving our clinics with funded life-changing medication.

Khiron begins dispensation of insurance-covered prescriptions in Colombia

Retrieved on: 
Thursday, January 19, 2023
Government, Insurance, Mental health, Quality of life, Chronic pain, Patient, Sleep, Health insurance, Pharmaceutical industry, Khiron Oonchaiyaphum

Following the Government of Colombia's decision on insurance coverage for medical cannabis, Khiron has begun dispensing medical cannabis to its patient base under the new mandate.

Key Points: 
  • Following the Government of Colombia's decision on insurance coverage for medical cannabis, Khiron has begun dispensing medical cannabis to its patient base under the new mandate.
  • ZereniaTM is a healthcare network of specialized clinics focused on treating chronic pain, neurological conditions, mental health, and sleep disorders.
  • It is the leading medical cannabis clinic network in Colombia, as evidenced by its recent contract with Colombia´s largest public insurance company.
  • Alvaro Torres, CEO of Khiron, comments: "Thanks to the wise decision from the Government of Colombia to cover medical cannabis prescriptions, more and more of our patients are leaving our clinics with funded life-changing medication.

NHS reimburses the cost of cannabis treatment to the first Zerenia™ Clinics UK patient

Retrieved on: 
Monday, January 16, 2023
Khiron Oonchaiyaphum, Clinic, United Kingdom, Canary Wharf, Anxiety, Safety, RWE, Patient, International Congress on Tuberculosis, NHS, Pain, Pharmaceutical industry, Cannabis

The patient was referred to the team at Zerenia™ Clinics UK for assistance with evaluation and advice on cannabis-based treatment options.

Key Points: 
  • The patient was referred to the team at Zerenia™ Clinics UK for assistance with evaluation and advice on cannabis-based treatment options.
  • Franziska Katterbach, President of Khiron Europe, comments: "There is huge demand for medicinal cannabis in the UK.
  • More than 1.4 million British self-medicate illegally with cannabis, half of whom medicate every day, with a total spend on illicit cannabis is an estimated £2.6 billion every year.
  • On top of that, the estimated wait times for NHS specialist consultations range drastically, but in certain areas can be up to nine months.

NHS reimburses the cost of cannabis treatment to the first Zerenia™ Clinics UK patient

Retrieved on: 
Monday, January 16, 2023
Khiron Oonchaiyaphum, Clinic, United Kingdom, Canary Wharf, Anxiety, Safety, RWE, Patient, International Congress on Tuberculosis, NHS, Pain, Pharmaceutical industry, Cannabis

The patient was referred to the team at Zerenia™ Clinics UK for assistance with evaluation and advice on cannabis-based treatment options.

Key Points: 
  • The patient was referred to the team at Zerenia™ Clinics UK for assistance with evaluation and advice on cannabis-based treatment options.
  • Franziska Katterbach, President of Khiron Europe, comments: "There is huge demand for medicinal cannabis in the UK.
  • More than 1.4 million British self-medicate illegally with cannabis, half of whom medicate every day, with a total spend on illicit cannabis is an estimated £2.6 billion every year.
  • On top of that, the estimated wait times for NHS specialist consultations range drastically, but in certain areas can be up to nine months.

Khiron wins first medical cannabis contract with Colombia's largest public insurance company

Retrieved on: 
Monday, January 9, 2023
Mental health, Pain, Chronic pain, Health, Research, Bogotá City Council, City, Epilepsy, Patient, Insurance, EPS, Quality of life, CAD, Health insurance, Drug, Khiron Oonchaiyaphum, LATAM

On December 27, 2022, Zerenia (Khiron´s wholly owned medical cannabis clinic network) signed a contract with CAPITAL SALUD EPS, Colombia´s largest public insurance company, under which Zerenia will provide medical cannabis services and products to its patient population, directly reimbursed by CAPITAL SALUD EPS.

Key Points: 
  • On December 27, 2022, Zerenia (Khiron´s wholly owned medical cannabis clinic network) signed a contract with CAPITAL SALUD EPS, Colombia´s largest public insurance company, under which Zerenia will provide medical cannabis services and products to its patient population, directly reimbursed by CAPITAL SALUD EPS.
  • Zerenia has already begun treating the first cohort of CAPITAL SALUD´s patients with medical cannabis.
  • TORONTO, Jan. 9, 2023 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), continues to pioneer the medical cannabis market in LATAM by announcing that Zerenia has signed a contract with insurance CAPITAL SALUD EPS, to provide medical cannabis services and products to CAPITAL SALUD EPS patient population and has already begun treating the first cohort of patients.
  • Alvaro Torres, CEO of Khiron, comments: "The city of Bogota has embraced medical cannabis as a catalyst for social and economic growth.

Khiron wins first medical cannabis contract with Colombia's largest public insurance company

Retrieved on: 
Monday, January 9, 2023
Mental health, Pain, Chronic pain, Health, Research, Bogotá City Council, City, Epilepsy, Patient, Insurance, EPS, Quality of life, CAD, Health insurance, Drug, Khiron Oonchaiyaphum, LATAM

On December 27, 2022, Zerenia (Khiron´s wholly owned medical cannabis clinic network) signed a contract with CAPITAL SALUD EPS, Colombia´s largest public insurance company, under which Zerenia will provide medical cannabis services and products to its patient population, directly reimbursed by CAPITAL SALUD EPS.

Key Points: 
  • On December 27, 2022, Zerenia (Khiron´s wholly owned medical cannabis clinic network) signed a contract with CAPITAL SALUD EPS, Colombia´s largest public insurance company, under which Zerenia will provide medical cannabis services and products to its patient population, directly reimbursed by CAPITAL SALUD EPS.
  • Zerenia has already begun treating the first cohort of CAPITAL SALUD´s patients with medical cannabis.
  • TORONTO, Jan. 9, 2023 /PRNewswire/ -- Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), continues to pioneer the medical cannabis market in LATAM by announcing that Zerenia has signed a contract with insurance CAPITAL SALUD EPS, to provide medical cannabis services and products to CAPITAL SALUD EPS patient population and has already begun treating the first cohort of patients.
  • Alvaro Torres, CEO of Khiron, comments: "The city of Bogota has embraced medical cannabis as a catalyst for social and economic growth.

Government of Colombia Declares Mandatory Insurance Coverage for Medical Cannabis Products

Retrieved on: 
Thursday, January 5, 2023
Government, Sleep, Ministry, Epilepsy, IETS, Ministry of Health and Medical Education, Patient, Insurance, Institute of technology, Fibromyalgia, Cannabis, Health insurance, Drug, Khiron Oonchaiyaphum, Health

This revision was necessary to remove unintended ambiguities that had arisen whether plant-based magistral preparations from medical cannabis (i.e., Khiron products) were also included in the insurance coverage.

Key Points: 
  • This revision was necessary to remove unintended ambiguities that had arisen whether plant-based magistral preparations from medical cannabis (i.e., Khiron products) were also included in the insurance coverage.
  • The new government is fully committed with the use of medical cannabis as a covered treatment under the Colombian health system.
  • This is the first time an insurance company in Latin America is contracting medical cannabis specific services and products.
  • We welcome the decision from the new Colombian government to categorically mandate insurance coverage for our medical cannabis products.

Khiron Life Sciences Reports Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 30, 2022
Corporation, Growth, THC, Pharmacy, EBITDA, United Kingdom, Conference, Insurance, Patient, Government, Q&A, Stock, RSU, Tax, Ratio, Depreciation, Loss, Acquisition, Pharmaceutical industry, Drug, Khiron Oonchaiyaphum

The Pharmadrug acquisition enables Khiron to sell directly to pharmacies in Germany without the need for a third-party distribution partner.

Key Points: 
  • The Pharmadrug acquisition enables Khiron to sell directly to pharmacies in Germany without the need for a third-party distribution partner.
  • The acquisition formally closed on August 2nd, 2022, after the clearance certificate required under German Foreign Trade Regulation was obtained.
  • Khiron invites individual and institutional investors, as well as advisors and analysts, to attend the Corporation's Third Quarter 2022 Conference Call, followed by a Q&A session.
  • PRESENTERS: Alvaro Torres, Khiron Chief Executive Officer and Director, Helen Bellwood, Khiron Chief Financial Officer, and Franziska Katterbach, President of Khiron Europe.

Khiron Life Sciences Reports Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 30, 2022
Corporation, Growth, THC, Pharmacy, EBITDA, United Kingdom, Conference, Insurance, Patient, Government, Q&A, Stock, RSU, Tax, Ratio, Depreciation, Loss, Acquisition, Pharmaceutical industry, Drug, Khiron Oonchaiyaphum

The Pharmadrug acquisition enables Khiron to sell directly to pharmacies in Germany without the need for a third-party distribution partner.

Key Points: 
  • The Pharmadrug acquisition enables Khiron to sell directly to pharmacies in Germany without the need for a third-party distribution partner.
  • The acquisition formally closed on August 2nd, 2022, after the clearance certificate required under German Foreign Trade Regulation was obtained.
  • Khiron invites individual and institutional investors, as well as advisors and analysts, to attend the Corporation's Third Quarter 2022 Conference Call, followed by a Q&A session.
  • PRESENTERS: Alvaro Torres, Khiron Chief Executive Officer and Director, Helen Bellwood, Khiron Chief Financial Officer, and Franziska Katterbach, President of Khiron Europe.

Khiron to Host Third Quarter 2022 Conference Call on November 30, 2022

Retrieved on: 
Friday, November 18, 2022
Conference, SEDAR, Legislation, Risk, Q&A, Prescription, Multimedia, Conference call, Patient, Nature, Comment, Pharmaceutical industry, Fine chemical, Public relations, Khiron Oonchaiyaphum

These filings will be available for review on the Company's SEDAR profile at www.sedar.com

Key Points: 
  • These filings will be available for review on the Company's SEDAR profile at www.sedar.com
    Khiron invites individual and institutional investors, as well as advisors and analysts, to attend the Company's Third Quarter 2022 Conference Call, followed by a Q&A session.
  • PRESENTERS: Alvaro Torres, Khiron Chief Executive Officer and Director, Helen Bellwood, Khiron Chief Financial Officer, and Franziska Katterbach, President of Khiron Europe.
  • About Khiron Life Sciences Corp.
    Khiron is a leading global medical cannabis company with core operations in Latin America and Europe.
  • Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable).